You are here

AstraZeneca

A Spark Of Good News For Precision Oncology In Breast Cancer

Forbes

Wed, 11/14/18 - 09:59 am

triple negative breast cancer

precision medicine

AstraZeneca makes $1B-plus in cash-and-stock deal granting Sobi US rights to RSV drug Synagis

Endpoints

Tue, 11/13/18 - 10:29 am

AstraZeneca calls victory in CV study, but will payers feel the same?

Biopharma Dive

Mon, 11/12/18 - 11:30 pm

FDA Accepts sNDA for Lynparza for Maintenance Therapy in Advanced Ovarian Cancer and Grants Priority Review

CP Wire

Mon, 11/12/18 - 10:19 am

FDA Accepts sNDA for Lynparza for Maintenance Therapy in Advanced Ovarian Cancer and Grants Priority Review

Mon, 11/12/18 - 09:54 am

AstraZeneca's diabetes drug curbs heart failure, kidney risks

Yahoo/Reuters

Sun, 11/11/18 - 09:14 pm

PARP makers search for a way to break through

Biopharma Dive

Fri, 11/9/18 - 12:08 am

Clovis Oncology

PARP inhibitors

AstraZeneca Reports First Quarter of Sustainable Product Sales Growth Since 2014

BioSpace

Thu, 11/8/18 - 12:24 pm

AZ drops midstage cancer drug vistusertib

Fierce Biotech

Thu, 11/8/18 - 12:17 pm

mTOR inhibitors

AstraZeneca Unloads Three Asthma and Rhinitis Drugs to Covis Pharma for $350 Million

BioSpace

Tue, 11/6/18 - 11:46 am

In another try at lung cancer niche, J&J nabs a potential Tagrisso rival for $50M-plus

Endpoints

Mon, 11/5/18 - 07:17 pm

AstraZeneca hands over some rights to Nexium, Vimovo to Grünenthal as it plots turnaround

Endpoints

Tue, 10/30/18 - 10:24 am

Grünenthal GmbH

PARPs may be crushing it in the clinic, but half of doctors are still wary: executive

Fierce Pharma

Wed, 10/24/18 - 12:38 pm

PARP inhibitors

Clovis Oncology

AstraZeneca gets rights, options to basket of next-gen immuno-oncology therapies from Innate

BioCentury

Tue, 10/23/18 - 11:02 pm

AstraZeneca and Ionis target diabetes with antisense approach to regenerating pancreatic cells

Fierce Biotech

Mon, 10/22/18 - 12:17 pm

Ionis Pharmaceuticals

type 2 diabetes

Mammoth Lynparza survival win puts AZ, Merck in line for $1B launch

Fierce Pharma

Sun, 10/21/18 - 11:33 pm

PARP inhibitors

BRCA-mutated ovarian cancer

ESMO18: Novartis PI3K combo therapy boosts survival in subset of breast cancer patients

Fierce Biotech

Sat, 10/20/18 - 11:10 pm

AstraZeneca, Merck’s Lynparza gets FDA ODD for pancreatic cancer

Pharmaceutical Business Review

Wed, 10/17/18 - 09:11 am

pancreatic cancer

AZ to continue with investment freeze following ‘no deal’ Brexit

Pharmaforum

Tue, 10/16/18 - 11:37 am

drug manufacturing

AstraZeneca: building a new ‘open innovation’ pharma company

PM Live

Mon, 10/15/18 - 11:57 pm

Pages